tradingkey.logo
tradingkey.logo
Search

Dare Bioscience Inc

DARE
Add to Watchlist
0.657USD
+0.013+2.02%
Close 11-13 16:00(ET)
12.92MMarket Cap
LossP/E TTM

Dare Bioscience Inc (DARE) Stock Price Target & Forecast

Analyst Rating

Based on 3 analysts giving stock ratings to Dare Bioscience Inc in the past month.

Buy
0 Strong Buy
3 Buy
0 Hold
0 Sell
0 Strong Sell
Target Price
8.333USD+1091.16%

DARE Analyst Recommendation Trends

In the current month, DARE has received 3 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. DARE average Analyst price target in the last month is 8.333.

2026-11
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
Strong Buy
0
0
0
0
0
0
0
0
Buy
3
3
3
3
3
4
4
4
Hold
0
0
0
0
0
0
0
0
Strong Sell
0
0
0
0
0
0
0
0
Sell
0
0
0
0
0
0
0
0
Total
3
3
3
3
3
4
4
4

DARE Analyst Rating for Peer Comparison

Updated: Nov 5, 2026
Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Ratings
Analysts
Biogen Inc
BIIB
8
16
12
1
0
37
Amgen Inc
AMGN
4
9
19
3
1
36
Vertex Pharmaceuticals Inc
VRTX
10
17
5
0
1
33
Eli Lilly and Co
LLY
10
19
3
1
0
33
Alnylam Pharmaceuticals Inc
ALNY
7
17
8
0
0
32
AbbVie Inc
ABBV
8
18
6
0
0
32
Neurocrine Biosciences Inc
NBIX
13
14
4
0
0
31
Merck & Co Inc
MRK
7
16
8
0
0
31
Gilead Sciences Inc
GILD
7
18
5
0
0
30
Bristol-Myers Squibb Co
BMY
5
6
18
1
0
30

Financial Forecasting

Based on analysts' estimates, DARE EPS is projected to reach -0.260 in FY2026Q3, following reported EPS of -0.200 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.

EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-0.43
-0.29
-0.24
-0.26
-0.23
Actual
-0.10
-0.21
-0.20
--
--
Surprise
+76.67%
+28.77%
+18.24%
--
--

FAQs

What is Dare Bioscience Inc's expected revenue for the next quarter?

Dare Bioscience Inc's expected revenue is 2.02M.

What is Dare Bioscience Inc's price target?

Analysts forecast that Dare Bioscience Inc's price target is USD 8.33, with the highest forecast at USD 12.00 and the lowest forecast at USD 5.00.

How have Dare Bioscience IncDARE's recent earnings per share performed?

The market expectation was USD -0.20, while Dare Bioscience IncDARE's earnings per share (EPS) for the previous quarter was USD -0.21. EPS for the next quarter is expected at USD -0.26.

What is the analyst rating for Dare Bioscience Inc?

Based on the ratings of Dare Bioscience Inc's stock from 3 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.